These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21543897)

  • 1. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
    Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
    Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
    Wang S; Pashtan I; Tsutsumi S; Xu W; Neckers L
    Cell Cycle; 2009 Jul; 8(13):2050-6. PubMed ID: 19502802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
    Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
    BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
    Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
    Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
    Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
    Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
    Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
    Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
    Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
    Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
    Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
    Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET oncogene inhibition as a potential target of therapy for uveal melanomas.
    Abdel-Rahman MH; Boru G; Massengill J; Salem MM; Davidorf FH
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3333-9. PubMed ID: 20164465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.
    Lee WY; Chen HH; Chow NH; Su WC; Lin PW; Guo HR
    Clin Cancer Res; 2005 Mar; 11(6):2222-8. PubMed ID: 15788670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
    Yao HP; Tong XM; Hudson R; Wang MH
    J Exp Clin Cancer Res; 2020 Sep; 39(1):198. PubMed ID: 32962738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
    Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
    Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis.
    Zhuang XP; Jin WW; Teng XD; Yuan ZZ; Lin QQ; Xu ST
    Eur J Gynaecol Oncol; 2015; 36(3):255-9. PubMed ID: 26189249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.